Pharma BD Deal Intelligence

MorphoSys AG / Constellation Pharmaceuticals, Inc.

2021 · Acquisition/Merger · $1.7B · Complete

Announcement Sentiment

Neutral / mixed

MorphoSys agreed to acquire Constellation Pharmaceuticals for $34.00 per share (~$1.7B total equity value). Lead assets include Phase III BET inhibitor pelabresib for myelofibrosis and Phase II EZH2 inhibitor CPI-0209. Royalty Pharma provided $1.425B in funding to support the transaction.

Key facts

Announced Jun 02, 2021
Closed Jul 15, 2021
Deal value $1.7B
Deal type Acquisition/Merger
Therapeutic area Myelofibrosis (BET inhibitor) and hematologic/solid tumors (EZH2 inhibitor)
Indications Myelofibrosis (BET inhibitor) and hematologic/solid tumors (EZH2 inhibitor)
Key assets Pelabresib (CPI-0610) and CPI-0209
Mechanism BET bromodomain inhibitor (pelabresib); EZH2 inhibitor (CPI-0209)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals